150008-24-5

Basic information

• Product Name: TERT-BUTYL 4-(HYDROXYIMINO)PIPERIDINE-1-CARBOXYLATE
• Synonyms: TERT-BUTYL 4-(HYDROXYIMINO)PIPERIDINE-1-CARBOXYLATE;1-Piperidinecarboxylic acid, 4-(hydroxyiMino)-, 1,1-diMethylethyl ester;1-Boc-4-(hydroxyimino)piperidine;tert-Butyl 4-(hydroxyimino)
• CAS NO: 150008-24-5
• Molecular Formula: C₁₀H₁₈N₂O₃
• Molecular Weight: 214.263
• Mol File: 150008-24-5.mol
• Article Data: 20

Chemical Properties

• Boiling Point: 333°C at 760 mmHg
• Flash Point: 155.2°C
• Appearance: /
• Density: 1.16g/cm³
• Vapor Pressure: 2.7E-05mmHg at 25°C
• Refractive Index: 1.521
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• CAS DataBase Reference: TERT-BUTYL 4-(HYDROXYIMINO)PIPERIDINE-1-CARBOXYLATE(CAS DataBase Reference)
• NIST Chemistry Reference: TERT-BUTYL 4-(HYDROXYIMINO)PIPERIDINE-1-CARBOXYLATE(150008-24-5)
• EPA Substance Registry System: TERT-BUTYL 4-(HYDROXYIMINO)PIPERIDINE-1-CARBOXYLATE(150008-24-5)

Safety Data

• Hazardous Substances Data: 150008-24-5(Hazardous Substances Data)

Usage

Uses

tert-Butyl 4-(hydroxyimino)piperidine-1-carboxylate is a useful intermediate for organic synthesis.

InChI:InChI=1/C10H18N2O3/c1-10(2,3)15-9(13)12-6-4-8(11-14)5-7-12/h14H,4-7H2,1-3H3

Upstream product

• 79099-07-3 N-tert-butyloxycarbonylpiperidin-4-one 
• 497-19-8 sodium carbonate 

Downstream Products

• 190900-21-1 5-oxo-[1,4]diazepane-1-carboxylic acid tert-butyl ester 
• 796062-33-4 3-amino-4,4-diethoxy-piperidine-1-carboxylic acid tert-butyl ester 
• 1354910-18-1 tert-butyl 2-(4-hydroxyphenyl)-6,7-dihydrooxazolo[4,5-c]pyridine-5(4H)-carboxylate 
• 1092464-33-9 1-(m-tolylsulfonyl)piperidin-4-one O-4-fluorophenylcarbamoyl oxime 
• 1092464-57-7 piperidin-4-one O-4-fluorophenylcarbamoyl oxime 
• 160431-84-5 1-(piperidin-4-yl)-3-(3-(trifluoromethyl)phenyl)urea 
• 160431-85-6 1-(piperidin-4-yl)-3-(4-(trifluoromethyl)phenyl)urea 
• 1056674-53-3 1-(1-acetylpiperidin-4-yl)-3-(4-tert-butyl-cyclohexyl)urea 
• 1332707-96-6 C₁₆H₃₁N₃O 

Relevant articles and documents

FUSED BICYCLIC RAF INHIBITORS AND METHODS FOR USE THEREOF

The present disclosure generally relates to improved synthesis of fused bicyclic Raf inhibitors of formula (I), (I-A), (I-B), (II), or (III), or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof. The disclosure also relates to method o

sEH Inhibitor or pharmaceutically acceptable composition thereof as well as preparation method and application thereof

The invention provides sEH inhibitor or a pharmaceutically acceptable composition and a preparation method and application thereof, and belongs to the technical field of medicines. sEH Inhibitor or a pharmaceutically acceptable composition thereof according to the present invention is provided, and the sEH inhibitor has the structure shown I. sEH Inhibitor provided by the invention can stabilize an endogenous substance epoxy fatty acid with wide physiological activity, has a strong inhibition effect on human recombinant sEH, and can be used for regulating the generation of a plurality of pro-inflammatory cytokines. The invention relieves the stress of endoplasmic reticulum, prevents or reverses the dysfunction of endothelial dysfunction, stabilizes mitochondria function multiple action mechanisms to obviously relieve neuropathic pain, and can effectively avoid adverse reactions related to the target spot. Furthermore, the sEH inhibitor structure provided by the invention does not contain free carboxyl groups, can avoid adverse reactions such as gastrointestinal irritation caused by oral administration, and is small in adverse reaction, high in bioavailability, excellent in analgesic effect and small in administration amount.

NOVEL PHENYL AND PYRIDYL UREAS ACTIVE AGAINST THE HEPATITIS B VIRUS (HBV)

The present invention relates generally to novel antiviral agents. Specifically, the present invention relates to compounds which can inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV replication cycle, compositions comprising such compounds, methods for inhibiting HBV viral replication, methods for treating or preventing HBV infection, and processes and intermediates for making the compounds.